Corcept Therapeutics experienced significant operational growth, marked by record prescription volumes, expanded commercial reach, and strong financial results with annual revenues scaling significantly. The company successfully advanced its extensive clinical pipeline—highlighted by regulatory progress for its oncology treatments and ongoing Phase 2 and Phase 3 clinical trials targeting cortisol-related diseases, metabolic disorders, and neurodegenerative conditions.